Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA-001 SAD and MAD Study in Healthy and Elderly Subjects
NCT07518771Phase 1Completed
- Sponsor
- PeptiDream Inc.
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PA-001 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by PeptiDream Inc. Primary endpoints: Incidence and severity of adverse events at 8 weeks, Incidence of laboratory abnormalities at 8 weeks and 1 more. Started Jul 2024; status: completed.
02
Drugs
PA-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07518771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518771.